Morgan Stanley
CNTA

Morgan Stanley’s Centessa Pharmaceuticals CNTA Stock Holding History

Morgan Stanley’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$170M Buy
4,268,353
+3,159,255
+285% +$80.8M 0.01% 1054
2025
Q4 		$27.7M Sell
1,109,098
-15,347
-1% -$389K ﹤0.01% 2631
2025
Q3 		$27.3M Sell
1,124,445
-669,026
-37% -$11.9M ﹤0.01% 2580
2025
Q2 		$23.6M Sell
1,793,471
-1,143,996
-39% -$14.5M ﹤0.01% 2638
2025
Q1 		$42.2M Buy
2,937,467
+1,012,958
+53% +$16.6M ﹤0.01% 1959
2024
Q4 		$32.2M Buy
1,924,509
+544,858
+39% +$9.03M ﹤0.01% 2263
2024
Q3 		$22.1M Sell
1,379,651
-670,741
-33% -$8.22M ﹤0.01% 2702
2024
Q2 		$18.5M Sell
2,050,392
-86,973
-4% -$825K ﹤0.01% 2749
2024
Q1 		$24.2M Sell
2,137,365
-290,735
-12% -$2.75M ﹤0.01% 2497
2023
Q4 		$19.3M Buy
2,428,100
+1,470,149
+153% +$9.86M ﹤0.01% 3375
2023
Q3 		$6.2M Buy
957,951
+133,322
+16% +$912K ﹤0.01% 3561
2023
Q2 		$5.1M Buy
824,629
+80,722
+11% +$383K ﹤0.01% 3766
2023
Q1 		$2.86M Buy
743,907
+428,772
+136% +$1.57M ﹤0.01% 4218
2022
Q4 		$977K Buy
315,135
+298,641
+1,811% +$1.11M ﹤0.01% 4886
2022
Q3 		$67K Sell
16,494
-23,770
-59% -$109K ﹤0.01% 6264
2022
Q2 		$196K Buy
40,264
+18,652
+86% +$119K ﹤0.01% 5911
2022
Q1 		$194K Buy
21,612
+7,527
+53% +$68.6K ﹤0.01% 5938
2021
Q4 		$158K Buy
14,085
+6,455
+85% +$86.9K ﹤0.01% 6182
2021
Q3 		$128K Buy
+7,630
New +$158K ﹤0.01% 6223

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Morgan Stanley's CNTA Position: Q1 2026 in Review

Morgan Stanley increased its Centessa Pharmaceuticals (CNTA) stake by 285% in Q1 2026, buying an estimated $80.8M and bringing the position to 4,268,353 shares worth $170M. The position accounts for 0.01% of the portfolio, ranked #1054.

Morgan Stanley first reported a position in CNTA in Q3 2021 and has held it in 19 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Morgan Stanley held 4,268,353 shares of Centessa Pharmaceuticals worth $170M as of Q1 2026.
  • Morgan Stanley bought 3,159,255 Centessa Pharmaceuticals shares in Q1 2026, an estimated $80.8M.
  • Centessa Pharmaceuticals made up 0.01% of Morgan Stanley's portfolio in Q1 2026, its #1054 holding.
  • Morgan Stanley first reported a position in Centessa Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.